Background
Phase III, open-label study (Children's Oncology Group AHOD0831). 166 patients aged ≤21 years with high-risk classical Hodgkin lymphoma: stage IIB with bulk or extranodal disease, stage IIIB, IVA, or IVB. Tested response-adaptive chemotherapy intensification for slow early responders (SER) using the ABVE-PC backbone with consolidative RT, examining whether DECA (dexamethasone, etoposide, cisplatin, cytarabine) salvage can rescue poor initial responders.
Interventions and follow up
Induction (all): 2 cycles ABVE-PC, then response assessment
Arm A (RER): 2 additional cycles ABVE-PC + IFRT to initial sites (consolidative)
Arm B (SER): DECA salvage × 2 cycles + 2 additional ABVE-PC + IFRT
Primary endpoint: 4-year event-free survival (EFS)
Median follow up: 5.0 years
Arm A (RER): 2 additional cycles ABVE-PC + IFRT to initial sites (consolidative)
Arm B (SER): DECA salvage × 2 cycles + 2 additional ABVE-PC + IFRT
Primary endpoint: 4-year event-free survival (EFS)
Median follow up: 5.0 years
Results
4-year EFS (RER): 86.6%
4-year EFS (SER, DECA rescue): 69.3%
4-year OS (RER): 96.2%
4-year OS (SER): 89.2%
SER rate: 29% of patients classified as SER after 2 cycles
4-year EFS (SER, DECA rescue): 69.3%
4-year OS (RER): 96.2%
4-year OS (SER): 89.2%
SER rate: 29% of patients classified as SER after 2 cycles
Adverse events
Hematologic (SER/DECA): Grade ≥3 neutropenia 88%; grade ≥3 anemia 58%; febrile neutropenia 47%
Other: Grade ≥3 ototoxicity (cisplatin) 12% in SER; bleomycin any-grade pulmonary toxicity ~5%; one DECA-related treatment death; long-term secondary malignancy risk from RT + alkylating agents
Other: Grade ≥3 ototoxicity (cisplatin) 12% in SER; bleomycin any-grade pulmonary toxicity ~5%; one DECA-related treatment death; long-term secondary malignancy risk from RT + alkylating agents
Conclusions
Response-adaptive DECA intensification for SER in high-risk pediatric cHL achieved a 4-year EFS of 69.3% — inferior to RER outcomes (86.6%) despite intensification, demonstrating that slow early response identifies a biologically high-risk population not fully rescued by additional chemotherapy.
Key Limitations
Small sample size (n=166) with non-randomized response-based allocation (RER vs SER) prevents formal comparison of intensification benefit. No control arm tested whether standard (non-DECA) therapy would yield similar SER outcomes. DECA intensification carries substantial myelosuppression, ototoxicity, and one treatment-related death. All patients received consolidative IFRT, precluding evaluation of RT omission and predating modern PET-adapted, brentuximab-containing regimens.
Clinical Context
AHOD0831 confirmed that slow early response marks a high-risk pediatric cHL population with inferior outcomes despite DECA intensification. The subsequent AHOD1331 trial established brentuximab vedotin + AVD as the new standard for high-risk pediatric cHL, superior to ABVE-PC. ASCO/COG-aligned current practice incorporates brentuximab-based frontline therapy and PET-adapted RT for this population.